Search - tctmd.com

Displaying 1 - 20 of 27

Sort: Relevancy | Date

Presentation ACC 2018

MANAGE: Dabigatran in Myocardial Injury After Noncardiac Surgery

Presenter: Philip Devereaux

March 12, 2018

Presentation AHA 2017

Clinical Benefit of Minimally-Interrupted Dabigatran versus Uninterrupted Warfarin for Catheter Ablation of Atrial Fibrillation: A Prospective Randomized Multicenter Trial

Presenter: Akihiko Nogami

November 13, 2017

Presentation TCT 2017

The RE-DUAL PCI Trial: Dabigatran in Patients With ACS and Atrial Fibrillation - How to Incorporate the Results in Clinical Practice

Presenter: Deepak L. Bhatt, C. Michael Gibson

November 01, 2017

Presentation TCT 2016

The RE-DUAL PCI Trial: Dabigatran in Patients With ACS and Atrial Fibrillation: Design, Rationale, and Status

Presenter: Freek W.A. Verheugt, Pascal Vranckx, Deepak L. Bhatt

November 01, 2016

Presentation TCT 2015

The RE-DUAL PCI Trial (Dabigatran in Patients With ACS and Atrial Fibrillation): Design, Rationale, and Status

Presenter: Pascal Vranckx, Deepak L. Bhatt

October 14, 2015

Presentation TCT 2015

Dabigatran: Analysis of Efficacy, Safety, and Special Considerations (Including Reversal Agents)

Presenter: Lisa K. Jennings, Matthew T. Roe, Pascal Vranckx

October 14, 2015

Presentation

RE-VERSE AD: Idarucizumab for Dabigatran Reversal

Presenter: Charles V. Pollack Jr

June 24, 2015

Presentation

Comparative Risk of GI Bleeding With Dabigatran, Rivaroxaban, and Warfarin: Population-Based Study

Presenter: Neena S. Abraham

May 01, 2015

Presentation

Site-Level Variation in and Practices Associated With Dabigatran Adherence

Presenter: S. Shore

April 15, 2015

Presentation

Risk of Bleeding With Dabigatran in A-fib

Presenter: I. Hernandez

November 04, 2014

Presentation TCT 2014

Dabigatran in ACS and Atrial Fibrillation: MI Risks, Safety in the Elderly, and the RE-DUAL Trial

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Laura Mauri

September 15, 2014

Presentation

Adherence to Dabigatran Therapy and Longitudinal Patient Outcomes: Insights From the VA

Presenter: S. Shore

April 17, 2014

Presentation

Meta-analysis of Randomized Controlled Trials on the Risk of Bleeding with Dabigatran

Presenter: B.J. Bloom

January 06, 2014

Presentation

Efficacy and Safety of Dabigatran vs. Warfarin in Relation to Baseline Renal Function in A-fib Patients

Presenter: Ziad Hijazi

December 23, 2013

Presentation

RE-COVER 2: Treatment of Acute VTE with Dabigatran or Warfarin and Pooled Analysis

Presenter: Sam Schulman

December 18, 2013

Presentation TCT 2013

Does Dabigatran Increase MI in Patients with Coronary Artery Disease? Addressing the Current Controversy

Presenter: Michael Ezekowitz

October 31, 2013

Presentation

Management and Outcomes of Major Bleeding During Treatment with Dabigatran or Warfarin

Presenter: A. Majeed

October 03, 2013

Presentation

Higher Persistence in Newly Diagnosed Nonvalvular A-fib Patients Treated with Dabigatran vs. Warfarin

Presenter: M. Zalesak

August 12, 2013

Presentation

RE-LY: Dabigatran vs. Warfarin and Hemorrhagic Stroke in Asians and Non-Asians with A-fib

Presenter: M. Hori

June 21, 2013

Presentation

Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation

Presenter: A.R. Harrington

April 05, 2013

Advertisement

MANAGE: Dabigatran in Myocardial Injury After Noncardiac Surgery

Clinical Benefit of Minimally-Interrupted Dabigatran versus Uninterrupted Warfarin for Catheter Ablation of Atrial Fibrillation: A Prospective Randomized Multicenter Trial

The RE-DUAL PCI Trial: Dabigatran in Patients With ACS and Atrial Fibrillation - How to Incorporate the Results in Clinical Practice

The RE-DUAL PCI Trial: Dabigatran in Patients With ACS and Atrial Fibrillation: Design, Rationale, and Status

The RE-DUAL PCI Trial (Dabigatran in Patients With ACS and Atrial Fibrillation): Design, Rationale, and Status

Dabigatran: Analysis of Efficacy, Safety, and Special Considerations (Including Reversal Agents)

RE-VERSE AD: Idarucizumab for Dabigatran Reversal

Comparative Risk of GI Bleeding With Dabigatran, Rivaroxaban, and Warfarin: Population-Based Study

Site-Level Variation in and Practices Associated With Dabigatran Adherence

Risk of Bleeding With Dabigatran in A-fib

Dabigatran in ACS and Atrial Fibrillation: MI Risks, Safety in the Elderly, and the RE-DUAL Trial

Adherence to Dabigatran Therapy and Longitudinal Patient Outcomes: Insights From the VA

Meta-analysis of Randomized Controlled Trials on the Risk of Bleeding with Dabigatran

Efficacy and Safety of Dabigatran vs. Warfarin in Relation to Baseline Renal Function in A-fib Patients

RE-COVER 2: Treatment of Acute VTE with Dabigatran or Warfarin and Pooled Analysis

Does Dabigatran Increase MI in Patients with Coronary Artery Disease? Addressing the Current Controversy

Management and Outcomes of Major Bleeding During Treatment with Dabigatran or Warfarin

Higher Persistence in Newly Diagnosed Nonvalvular A-fib Patients Treated with Dabigatran vs. Warfarin

RE-LY: Dabigatran vs. Warfarin and Hemorrhagic Stroke in Asians and Non-Asians with A-fib

Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content